DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its...
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported...
Instil Bio Announces Strategic Update
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil€ or the Company€) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte,...
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (œInstil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational...
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development,...
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H’2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11,...
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update